The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 56)
Improved Biomarkers & Clinical Outcome Measures, 2017
Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in Parkinson's Disease
This project will test a new idea for measuring the severity of Parkinson's disease (PD). The brain acts as if it can store each dose of levodopa (L DOPA) for a short period of time and lets it "leak" into the brain when needed. This levodopa reservoir appears to get "leakier" as PD progresses, contributing to a gradually briefer benefit from each dose of the drug. The new idea we...
Researchers: Kevin J. Black, MD
Improved Biomarkers & Clinical Outcome Measures, 2016
Amyloid fibrils play a key role in Parkinson's disease (PD). Studying their formation from self‐assembled aggregates (protein clumps) would help aid the development of a valuable diagnostic tool. Despite progress in understanding these processes in a test tube, visualization through an imaging approach has not yet been fully achieved. We will develop a contrast agent with protectiv...
Researchers: Leif Schröder, Dr. rer. nat.
PPMI Data Challenge, 2016
Multivariate Prediction of Parkinson's Disease Clinical Progression (2016 PPMI Data Challenge Winner)
Parkinson's disease (PD) is heterogeneous in both clinical representation and prognosis, as indicated by a large diversity of rates of progression in motor as well as non-motor symptoms. It could therefore be helpful to have well-characterized and distinct subtypes of Parkinson's disease slow and fast clinical progression and have early indicators of the clinical progression rate f...
Researchers: Duygu Tosun-Turgut, PhD
Research Grant, 2016
A substantial proportion of individuals with Parkinson's disease develop cognitive
impairment, or difficulty with thinking abilities. The basis for these changes is poorly
understood. We now can image the deposition of two abnormal proteins that accumulate in the brains of older individuals. These proteins, beta-amyloid and tau, can be imaged using positron emitting tomography (a typ...
Biomarkers Across Neurodegenerative Diseases, 2016
Alzheimer's disease (AD), Lewy Body Dementia (LBD) and frontotemporal dementia (FTD) are characterized by the accumulation of specific proteins in the brain. The identification of these proteins is necessary to make a definite diagnosis of AD, LBD or FTD but, unfortunately, it can be performed only on post-mortem brain tissue. Recently, a trace amount of these pathological protei...
Researchers: Fabio Moda, PhD